NCT03883607View on ClinicalTrials.gov

Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 25, 2019

Primary Completion Date

June 16, 2020

Study Completion Date

June 16, 2020

Conditions
Non Alcoholic Steatohepatitis
Interventions
DRUG

Elafibranor 80mg

Once daily oral intake of elafibranor 80 mg during 3 months

DRUG

Elafibranor 120mg

Once daily oral intake of elafibranor 120 mg during 3 months

Trial Locations (2)

10032

Columbia University, New York

92103

University of California, San Diego

Sponsors

Lead Sponsor

Genfit
All Listed Sponsors
lead

Genfit

INDUSTRY

NCT03883607 - Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH) | Biotech Hunter | Biotech Hunter